设计了一种膜蛋白伴侣,以改善突变狩猎的蛋白质毒性
Jeonghyun Oh1, Christy Catherine1, Eun Seon Kim2
1Center for Biomolecular and Cellular Structure, Institute for Basic Science (IBS), Daejeon, Republic of Korea.
Nature communications
|January 17, 2025
概括
研究人员设计了一种蛋白质陪伴剂,以防止亨廷顿病 (HD) 中的有毒聚合物形成. 这种新的方法有望通过向突变的亨廷丁蛋白聚合来延缓疾病的进展.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 有毒的蛋白质聚合物,如突变的亨廷丁 (mHttex1),是神经退行性疾病的标志,如亨廷顿病 (HD).
- 目前的HD治疗方法无法延缓疾病的进展,这凸显了针对潜在分子机制的新型治疗策略的需要.
研究的目的:
- 开发一种机制方法来防止与亨廷顿病相关的突变亨廷丁 (mHttex1) 的聚合.
- 为了设计独立于ATP的细胞质伴侣PEX19以准和去除mHttex1聚合物.
主要方法:
- 使用基于酵母毒性的查与随机突变库来识别PEX19变体.
- 对人类PEX19 (hsPEX19) 进行了同等突变的工程设计,并在体外和细胞 Hunt 模型中测试了它们的疗效.
- 使用结构分析研究了突变hsPEX19和mHttex1之间的结合相互作用.
主要成果:
- 确定了两个酵母PEX19变体和工程人类PEX19 (hsPEX19) 变体,这些变体有效地延迟了mHttex1的聚合.
- 证明突变hsPEX19与mHttex1的N17域结合,抑制初始聚合.
- 表明hsPEX19-FV变异过度表达在初级条纹神经元和多菌模型中拯救了与HD相关的表型.
结论:
- 工程ATP独立的膜蛋白陪伴体代表了对亨廷顿病的有前途的治疗策略.
- 通过陪伴工程准mHttex1聚合提供了一个合理的方法来潜在地减缓HD进展.
- 这项研究为开发特征为蛋白质聚合的神经退行性疾病的治疗提供了一种新的机制战略.
相关概念视频
03:00Molecular Chaperones and Protein Folding
17.7K
The native conformation of a protein is formed by interactions between the side chains of its constituent amino acids. When the amino acids cannot form these interactions, the protein cannot fold by itself and needs chaperones. Notably, chaperones do not relay any additional information required for the folding of polypeptides; the native conformation of a protein is determined solely by its amino acid sequence. Chaperones catalyze protein folding without being a part of the folded protein.
The...
The...
17.7K
01:32Export of Misfolded Proteins out of the ER
3.5K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
3.5K
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K